SEC Filing Analysis: Cardiff Lexington Corp (CDIX)

Executive Summary

• Trading Significance: Low
• Key Takeaway: A director received routine, non-cash compensation in the form of stock and option grants, indicating standard corporate governance practices rather than a significant market signal.
• Market Impact: Neutral, as these are scheduled compensation awards and not open-market trades.

Company Information

Field	Value
Company	Cardiff Lexington Corp
Ticker Symbol	CDIX
CIK	0000811222
Industry	SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE

Insider Information

Field	Value
Name	Staley Louis Jack Sr.
CIK	0002021563
Title/Position	null
Relationship	Director

Transaction Details

This filing reports three separate compensation awards from the company's 2024 Equity Incentive Plan.

Transaction 1: Stock Option Grant

Field	Value
Form Type	4
Transaction Date	2025-12-11
Transaction Code	A (Grant)
Security Type	Stock Option
Shares Involved	50,000
Price Per Share	$0.00
Total Value	$0
Shares Owned After	50,000 (options)
Ownership Type	Direct

Transactions 2 & 3: Restricted Stock Awards

Field	Value
Transaction Date	2025-09-26
Transaction Code	A (Grant)
Security Type	Common Stock
Shares Involved	10,000 (5,000 + 5,000)
Price Per Share	$0.00
Total Value	$0
Shares Owned After	20,000 (common stock)
Ownership Type	Direct

Financial Impact Assessment

Impact Evaluation

Without market capitalization or shares outstanding data, a quantitative assessment of materiality or dilution is not possible. However, the transactions are grants (Code 'A') with a $0 price, typical for equity-based compensation. They serve to align the director's interests with those of shareholders over the long term, contingent on vesting schedules.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: These transactions are non-market compensation awards and do not reflect an insider's decision to buy or sell shares with their own capital at market prices. Such grants are a routine part of executive and director compensation and are not typically interpreted as a new market signal.

Volume & Sentiment

• Expected Volume Impact: None. These are not open-market transactions and will not directly impact trading volume.
• Sentiment Indicator: Neutral. The filing confirms standard corporate compensation practices.

Additional Context

Transaction Notes

• Vesting Schedules: The awards are subject to vesting conditions as detailed in the footnotes:
  • 5,000 shares vested immediately on September 26, 2025.
  • 5,000 shares began vesting quarterly starting October 1, 2025.
  • The 50,000 stock options (exercise price $1.729, expires 2035-12-11) will vest quarterly over one year, starting January 1, 2026.
• Purpose: All transactions were grants under the Issuer's 2024 Equity Incentive Plan.